Gyeongsang National University Hospital Registry

NCT ID: NCT04650529

Last Updated: 2021-01-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

10000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-01-31

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The G-NUH registry is a two-center, real-world registry of percutaneous coronary intervention in patients with significant coronary artery disease. From January 2010, PCI-treated patients from Gyeonsang National University Hospitals (Jinju \& Changwon) were enrolled in this registry.

The aim of this registry is to investigate long-term clinical outcomes and predictors of adverse outcomes after percutaneous coronary intervention from the academic hospitals.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In the G-NUH registry, the investigators have collected and measured multiple hemostatic, physiologic and laboratory measurements (on-admission \& 1-month) and questionnarred from PCI-treated patients. This registry will focus on the impacts of these parameters on long-term clinical outcomes from East Asian patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Percutaneous Coronary Intervention Hemostatic Disorder Blood Clot

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

stent, ballooning

DES, BMS, BRS, DEB, and POBA can be used for PCI

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age \>= 18 years
* Significant coronary artery disease
* Treated with PCI
* Multiple hemostatic or physiologic measurements

Exclusion Criteria

* Medically treated cases
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Gyeongsang National University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Young-Hoon Jeong

Director, Cardiovascular Center

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Young-Hoon Jeong, MD, PhD

Role: STUDY_DIRECTOR

Changwon Gyeongsang National University Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Changwon Gyeongsang National University Hospital

Changwon, Gyeongsangnam-do, South Korea

Site Status RECRUITING

Gyeonsang National University Hospital

Jinju, Gyeonsangnam-do, South Korea

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

South Korea

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Jin Sin Koh, MD, PhD

Role: CONTACT

82-10-8544-0175

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Yongwhi Park, MD PhD

Role: primary

82-10-2173-7214

Jin Sin Koh, MD, PhD

Role: primary

82-10-8544-0175

References

Explore related publications, articles, or registry entries linked to this study.

Bae JS, Ahn JH, Jang JY, Cho SY, Kang MG, Kim KH, Park HW, Koh JS, Park Y, Hwang SJ, Kwak CH, Hwang JY, Tantry US, Gurbel PA, Jeong YH. The Impact of platelet-fibrin clot strength on occurrence and clinical outcomes of peripheral artery disease in patients with significant coronary artery disease. J Thromb Thrombolysis. 2020 Nov;50(4):969-981. doi: 10.1007/s11239-020-02103-w.

Reference Type RESULT
PMID: 32279217 (View on PubMed)

Omar M, Kang MG, Jung MK, Ahn JH, Koh JS, Guevarra PI, Kim SW, Tantry US, Gurbel PA, Hwang JY, Jeong YH. Association and Prognostic Implications of "No-Reflow Phenomenon" and Hypercoagulability in Patients With ST-Segment Elevation Myocardial Infarction. JACC Asia. 2025 Aug 25:S2772-3747(25)00390-4. doi: 10.1016/j.jacasi.2025.07.015. Online ahead of print.

Reference Type DERIVED
PMID: 40910963 (View on PubMed)

Cho S, Jung M, Ahn JH, Kang MG, Bae JS, Koh JS, Hwang SJ, Kim HS, Kim SW, Hwang JY, Jeong YH. Diabetic Status and Thrombogenicity: Association and Prognostic Implications After Percutaneous Coronary Intervention. JACC Cardiovasc Interv. 2025 Mar 24;18(6):720-733. doi: 10.1016/j.jcin.2024.12.002.

Reference Type DERIVED
PMID: 40139850 (View on PubMed)

Lee SY, Cho JY, Gorog DA, Angiolillo DJ, Yun KH, Ahn JH, Koh JS, Park Y, Hwang SJ, Hwang JY, Kim JW, Jang Y, Jeong YH. Inflammation and platelet reactivity during adjunctive colchicine versus aspirin in patients with acute coronary syndrome treated with potent P2Y12 inhibitor. Front Med (Lausanne). 2024 Apr 19;11:1349577. doi: 10.3389/fmed.2024.1349577. eCollection 2024.

Reference Type DERIVED
PMID: 38841588 (View on PubMed)

Lee SH, Kim HK, Ahn JH, Kang MG, Kim KH, Bae JS, Cho SY, Koh JS, Park Y, Hwang SJ, Gorog DA, Tantry US, Bliden KP, Gurbel PA, Hwang JY, Jeong YH. Prognostic impact of hypercoagulability and impaired fibrinolysis in acute myocardial infarction. Eur Heart J. 2023 May 14;44(19):1718-1728. doi: 10.1093/eurheartj/ehad088.

Reference Type DERIVED
PMID: 36857519 (View on PubMed)

Ahn JH, Tantry US, Kang MG, Park HW, Koh JS, Bae JS, Cho SY, Kim KH, Jang JY, Park JR, Park Y, Hwang SJ, Kwak CH, Hwang JY, Gurbel PA, Jeong YH. Residual Inflammatory Risk and its Association With Events in East Asian Patients After Coronary Intervention. JACC Asia. 2022 Apr 12;2(3):323-337. doi: 10.1016/j.jacasi.2021.11.014. eCollection 2022 Jun.

Reference Type DERIVED
PMID: 36338415 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

G-NUH

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Perfusion CT Registry
NCT01696006 COMPLETED